4.3 Article

The Role of Biomarkers in the Diagnosis and Management of Pneumonia

Journal

CLINICS IN CHEST MEDICINE
Volume 39, Issue 4, Pages 691-+

Publisher

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.ccm.2018.07.004

Keywords

Biomarkers; Pneumonia diagnosis; Procalcitonin; Scoring systems; Prognosis

Funding

  1. BioMerieux
  2. Roche Scientific
  3. ThermoFisher

Ask authors/readers for more resources

Biomarkers are used in the diagnosis, severity determination, and prognosis for patients with community-acquired pneumonia (CAP). Selected biomarkers may indicate a bacterial infection and need for antibiotic therapy (C-reactive protein, procalcitonin, soluble triggering receptor expressed on myeloid cells). Biomarkers can differentiate CAP patients who require hospital admission and severe CAP requiring intensive care unit admission. Biomarker-guided antibiotic therapy may limit antibiotic exposure without compromising outcome and thus improve antibiotic stewardship. The authors discuss the role of biomarkers in diagnosing, determining severity, defining the prognosis, and limiting antibiotic exposure in CAP and ventilator-associated pneumonia patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available